Differential effects of childhood trauma and cannabis use disorders in patients suffering from schizophrenia.
Schizophrenia Research. 2016-08-01; 175(1-3): 161-167
DOI: 10.1016/j.schres.2016.04.042
Lire sur PubMed
1. Schizophr Res. 2016 Aug;175(1-3):161-167. doi: 10.1016/j.schres.2016.04.042.
Epub 2016 May 18.
Differential effects of childhood trauma and cannabis use disorders in patients
suffering from schizophrenia.
Baudin G(1), Godin O(2), Lajnef M(3), Aouizerate B(4), Berna F(5), Brunel L(6),
Capdevielle D(7), Chereau I(8), Dorey JM(9), Dubertret C(10), Dubreucq J(11),
Faget C(12), Fond G(6), Gabayet F(11), Laouamri H(13), Lancon C(12), Le Strat
Y(10), Tronche AM(8), Misdrahi D(14), Rey R(9), Passerieux C(15), Schandrin
A(7), Urbach M(15), Vidalhet P(16), Llorca PM(8), Schürhoff F(17); FondaMental
Academic Centers of Expertise for Schizophrenia (FACE-SZ) Collaborators.
Author information:
(1)Fondation FondaMental, Créteil F94000, France; INSERM U955, Équipe de
Psychiatrie Translationnelle, Créteil F94000, France; AP-HP, DHU Pe-PSY, Pôle de
Psychiatrie des Hôpitaux Universitaires H Mondor, Créteil F94000, France;
Université François-Rabelais de Tours, PAV EA 2114, Tours F37000, France.
(2)Fondation FondaMental, Créteil F94000, France; Sorbonne Universités, UPMC
Univ Paris 06, INSERM, Institut Pierre Louis d’épidémiologie et de Santé
Publique (IPLESP UMRS 1136), F75013 Paris, France.
(3)INSERM U955, Équipe de Psychiatrie Translationnelle, Créteil F94000, France.
(4)Fondation FondaMental, Créteil F94000, France; Centre Hospitalier Charles
Perrens, F-33076, Bordeaux, France; Université de Bordeaux, France; Inserm,
Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U862,
F-33000, Bordeaux, France.
(5)Fondation FondaMental, Créteil F94000, France; Hôpitaux Universitaires de
Strasbourg, Université de Strasbourg, INSERM U1114, Fédération de Médecine
Translationnelle de Strasbourg, Strasbourg, France.
(6)Fondation FondaMental, Créteil F94000, France; INSERM U955, Équipe de
Psychiatrie Translationnelle, Créteil F94000, France; AP-HP, DHU Pe-PSY, Pôle de
Psychiatrie des Hôpitaux Universitaires H Mondor, Créteil F94000, France;
Université Paris-Est Créteil F94000, France.
(7)Fondation FondaMental, Créteil F94000, France; Service Universitaire de
Psychiatrie Adulte, Hôpital la Colombière, CHRU Montpellier, Université
Montpellier 1, Inserm 1061, Montpellier, France.
(8)Fondation FondaMental, Créteil F94000, France; CMP B, CHU, EA 7280 Faculté de
Médecine, Université d’Auvergne, BP 69, 63003 Clermont-Ferrand Cedex 1, France.
(9)Fondation FondaMental, Créteil F94000, France; Université Claude Bernard Lyon
1, Centre Hospitalier Le Vinatier, Pole Est BP 300 39, 95 bd Pinel, 69678 Bron
Cedex, France.
(10)Fondation FondaMental, Créteil F94000, France; AP-HP, Department of
Psychiatry, Louis Mourier Hospital, Colombes, Inserm U894, Université Paris
Diderot, Sorbonne Paris Cité, Faculté de Médecine, France.
(11)Fondation FondaMental, Créteil F94000, France; Centre Référent de
Réhabilitation Psychosociale, CH Alpes Isère, Grenoble, France.
(12)Fondation FondaMental, Créteil F94000, France; Assistance Publique des
Hôpitaux de Marseille (AP-HM), Pôle Universitaire de Psychiatrie, Marseille,
France.
(13)Fondation FondaMental, Créteil F94000, France.
(14)Fondation FondaMental, Créteil F94000, France; Université de Bordeaux,
France; Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, INSERM
U1114, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg,
France; CNRS UMR 5287-INCIA, France.
(15)Fondation FondaMental, Créteil F94000, France; Service de Psychiatrie
d’Adulte, Centre Hospitalier de Versailles, UFR des Sciences de la Santé Simone
Veil, Université Versailles Saint-Quentin en Yvelines, Versailles, France.
(16)Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, INSERM
U1114, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg,
France.
(17)Fondation FondaMental, Créteil F94000, France; INSERM U955, Équipe de
Psychiatrie Translationnelle, Créteil F94000, France; AP-HP, DHU Pe-PSY, Pôle de
Psychiatrie des Hôpitaux Universitaires H Mondor, Créteil F94000, France;
Université Paris-Est Créteil F94000, France. Electronic address:
.
BACKGROUND: Childhood trauma (CT) and cannabis use are both environmental and
modifier risk factors for schizophrenia. However, little is known about how they
interact in schizophrenia. We examined the main effect of each of these two
environmental factors on the clinical expression of the disease using a large
set of variables, and we tested whether and how cannabis and CT interact to
influence the course and the presentation of the illness.
METHODS: A sample of 366 patients who met the DSM-IV-TR criteria for
schizophrenia was recruited through the FACE-SCZ (Fondamental Advanced Centre of
Expertise – Schizophrenia) network. Patients completed a large standardized
clinical evaluation including Structured Clinical Interview for DSM Disorders-I
(SCID-I), Positive and Negative Symptoms Scale (PANSS), Columbia-Suicide
Severity Rating Scale (C-SSRS), Global Assessment of Functioning (GAF),
Short-Quality of Life-18 (S-QoL-18), and Medication Adherence Rating Scale
(MARS). We assessed CT with the Childhood Trauma Questionnaire and cannabis
status with SCID-I.
RESULTS: CT significantly predicted the number of hospitalizations, GAF, and
S-QoL-18 scores, as well as the PANSS total, positive, excitement, and emotional
distress scores. Cannabis use disorders significantly predicted age of onset,
and MARS. There was no significant interaction between CT and cannabis use
disorders. However, we found evidence of a correlation between these two risk
factors.
CONCLUSIONS: CT and cannabis both have differential deleterious effects on
clinical and functional outcomes in patients with schizophrenia. Our results
highlight the need to systematically assess the presence of these risk factors
and adopt suitable therapeutic interventions.
Copyright © 2016 Elsevier B.V. All rights reserved.
DOI: 10.1016/j.schres.2016.04.042
PMID: 27209524 [Indexed for MEDLINE]